triazoles has been researched along with quizartinib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Geng, J; Li, Y; Najafov, A; Ofengeim, D; Ouchida, AT; Sun, X; Yu, Q; Yuan, J | 1 |
| Cheng, T; Guo, D; Ma, X; Ren, Q; Wang, N; Yin, J; You, N; Zhang, P; Zhao, Y; Zhu, W | 1 |
2 other study(ies) available for triazoles and quizartinib
| Article | Year |
|---|---|
Synergistic effect of a novel autophagy inhibitor and Quizartinib enhances cancer cell death.
Topics: Apoptosis; Autophagy; Benzothiazoles; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Humans; Neoplasms; Oxazoles; Phenylurea Compounds; Receptor, ErbB-2; Signal Transduction; Triazoles | 2018 |
GADD45g acts as a novel tumor suppressor, and its activation suggests new combination regimens for the treatment of AML.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azepines; Benzothiazoles; Depsipeptides; fms-Like Tyrosine Kinase 3; Gene Expression Regulation, Neoplastic; HL-60 Cells; Humans; Intracellular Signaling Peptides and Proteins; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Mice, SCID; Mutation; Phenylurea Compounds; THP-1 Cells; Triazoles; Tumor Suppressor Proteins; U937 Cells; Up-Regulation | 2021 |